GEN Exclusives

More »

GEN Poll

More »
Oct 10, 2011

Buying Biotech

Amgen and Genentech have been synonymous with biotech. They long held the first two spots among biotechs based on market cap. In 2009, Roche, which already held 55.8% of Genentech, shelled out $46.8 billion to take over the rest of this biotech giant. That acquisition helped move Roche up to the number two spot among pharmas, but that meant Genentech was no longer second among biotechs. You can check out a list of the top 30 biotech companies by market cap by clicking here for intriguing biotech facts compiled for our 30th anniversary issue. Which of the current top three players do you think is being eyed by those in the pharma world?

Which of the following, if any, is most likely to get scooped up by big pharma?

Amgen
 
  26.1%
Gilead Sciences
 
  31.9%
Celgene
 
  23.2%
None of Them
 
  18.8%

More Polls » View Results »

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?